Long-term efficacy of topical minoxidil in male pattern baldness

1987 ◽  
Vol 16 (3) ◽  
pp. 711-718 ◽  
Author(s):  
Harry Irving Katz ◽  
Ngo T. Hien ◽  
Steven E. Prawer ◽  
Sandra J. Goldman
2012 ◽  
Vol 66 (1) ◽  
pp. e10-e12 ◽  
Author(s):  
Jee-Woong Choi ◽  
Se-Young Na ◽  
Kyoung-Chan Park ◽  
Sang-Woong Youn ◽  
Chang-Hun Huh

1990 ◽  
Vol 31 (1) ◽  
pp. 17-25 ◽  
Author(s):  
T.J. Connors ◽  
D.E. Cooke ◽  
W.E. De Launey ◽  
M. Downie ◽  
R.G. Knudsen ◽  
...  

1990 ◽  
Vol 2 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Georgina C. Pastorfide ◽  
Josephine G. Chua ◽  
Jesus L. Garcia ◽  
Guillermo T. Gutierez

2015 ◽  
Vol 2 (2) ◽  
pp. 90 ◽  
Author(s):  
Anil S. Gugle ◽  
Vikrant M. Jadhav ◽  
Rahul Kote ◽  
Milind Devidas Deshmukh ◽  
Aditi Vijay Dalvi

<strong>Background</strong>: Androgenetic alopecia (AGA) more commonly known as male pattern baldness affects up to 50% of men worldwide. Tretinoin prolongs anagen phase and increases percutaneous absorption of minoxidil three fold. Azelaic acid is an inhibitor of 5 alpha reductase and could be an effective agent in the treatment of androgen related pathology of human skin. <strong>Aims and Objective</strong>: 1) To study the efficacy of topical minoxidil 5% in treatment of androgenetic alopecia. 2) To study the efficacy of combination of topical minoxidil 5%, topical azelaic acid 1.5% and topical tretinoin 0.01% in treatment of androgenetic alopecia. 3) To compare the efficacy of foresaid topical preparation in treatment of androgenetic alopecia Setting: Outpatient department of Dermatology, Venerology Leprology of a tertiary health care centre with an attached medical college. <strong>Material and methods</strong>: Topical minoxidil 5 % lotion was used in 23 (50%) patients of the present study. Combination of topical minoxidil 5%, azelaic acid 1.5 % and tretinoin 0.01 % lotion was used in 23 (50 %) patients of the present study. <strong>Statistical analysis used</strong>: Epi info version 7. Results: There was statistically significant increase in hair number and thickness after treatment in both the groups. The comparison of the increase of hair number and thickness was statistically insignificant. <strong>Conclusions</strong>: Topical Minoxidil 5% is equally effective to combination of topical Minoxidil 5%, azelaic acid 1.5% and tretinoin 0.01% in treatment of androgenetic alopecia.


1989 ◽  
Vol 14 (1) ◽  
pp. 40-46 ◽  
Author(s):  
D.H. RUSHTON ◽  
W. P. UNGER ◽  
P. C. COTTERILL ◽  
P. KINGSLEY ◽  
K. C. JAMES

1986 ◽  
Vol 15 (1) ◽  
pp. 30-37 ◽  
Author(s):  
Elise A. Olsen ◽  
Elizabeth R. DeLong ◽  
Madeline S. Weiner

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Leonardo Azevedo Mobilia Alvares ◽  
Flávia Siqueira Cunha ◽  
Tainã Aci Amaral Oliveira ◽  
Berenice Bilharinho Mendonca ◽  
Elaine Maria Frade Costa ◽  
...  

Abstract Introduction: Association between male pattern baldness, also called androgenetic alopecia (AGA) and risk of coronary artery disease has been suggested by several epidemiological studies. Exogenous testosterone (T) therapy in transgender men (TM) promotes the development of alopecia in genetically susceptible individuals, and increases facial and body hair, muscle mass (MM) and visceral fat. The outcome of a long-term androgenic therapy over the functional properties of large arteries and the cardiovascular system of TM are not well stablished. Objective: To investigate the possible association between AGA and arterial stiffness assessed by measurement of carotid-femoral pulse wave velocity (VOPcf) and intima-media thickness carotid artery (cIMT) in TM receiving long-term T therapy. Methods: Forty-six TM (mean age: 43 ± 10 yo) undergoing T therapy (mean time of treatment duration: 13 ± 10 y; mean serum T levels: 611 ± 439 ng/dL) were evaluated in a cross-sectional study. Hair pattern (Ferriman & Gallway scale), grades of male pattern baldness (Hamilton-Norwood scale) and waist-hip ratio (WHR) were analyzed. Subjects were considered to have AGA if they have vertex alopecia (grade ≥ 3). Arterial Hypertension was defined as systolic blood pressure &gt; 140 and/or diastolic blood pressure &gt; 90mmHg or under pharmacological treatment, and dyslipidemia as total cholesterol ≥ 240 mg/dL and/or LDL-c≥ 160 mg/dL and/or HDL-c &lt; 40 mg/dL and/or triglycerides &gt; 200 mg/dL, or under pharmacological treatment. Current smoking has been investigated. The aortic stiffness, assessed by VOPcf and cIMT, was measured using the Complior® device and carotid ultrasound, respectively. Results: TM’s Ferriman degree was 21 ± 6 and AGA was identified in 70% of them. The WHR was 0.9 ± 0.1. TM with AGA showed higher cIMT than TM without AGA (0.66 ± 0.1mm vs. 0.54 ± 0.07mm, p = 0.001), as well as higher WHR (0.93 ± 0.08 vs.0.87 ± 0.04, p = 0.02), higher score in terminal body hair (Ferriman 23 ± 6 vs. 18 ± 6, p = 0.007) and higher frequency of hypertension (94% vs. 6%, p = 0.01). The cIMT positively correlated with age (p = 0.01) and WHR (p = 0.002). The VOPcf was positively correlated with the age (p = 0.0001), androgen treatment duration (p = 0.01) and WHR (p = 0.04). There was a positive correlation between androgen treatment duration and WHR (p = 0.01). There was no difference in the VOPcf values, age, T treatment duration, serum T levels, frequency of dyslipidemia and smoking between the groups. Conclusion: The severe vertex AGA pattern may be considered a possible marker of arterial stiffness in TM undergoing long-term testosterone therapy.


Sign in / Sign up

Export Citation Format

Share Document